IOVA Quote, Financials, Valuation and Earnings

KalVista Pharmaceuticals, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -361.39%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

Iovance Biotherapeutics, Inc. has a consensus price target of $9.11, signalling upside risk potential of 217.46%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 114.78%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.191, suggesting its less volatile than the S&P 500 by 119.067%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.80x versus 54.92x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lantheus Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 7.23%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Iovance Biotherapeutics, Inc. has a consensus price target of $9.11, signalling upside risk potential of 217.46%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $84.62 which suggests that it could grow by 14.55%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.076, suggesting its less volatile than the S&P 500 by 107.602%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 31.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.80x versus 3.37x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of --. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Protokinetix, Inc.'s return on equity of -111.59%.

Iovance Biotherapeutics, Inc. has a consensus price target of $9.11, signalling upside risk potential of 217.46%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Protokinetix, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Protokinetix, Inc. quarterly revenues of --. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.80x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -316.61%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Plus Therapeutics, Inc.'s return on equity of --.

Iovance Biotherapeutics, Inc. has a consensus price target of $9.11, signalling upside risk potential of 217.46%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.80x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.